Literature DB >> 1336009

An analysis of peripheral type benzodiazepine receptors on blood mononuclear cells during high dose steroid treatment of multiple sclerosis.

P Ferrero1, P Rocca, P Benna, C De Leo, E Montalenti, L Ravizza, B Bergamasco.   

Abstract

We report here a study of peripheral type benzodiazepine receptors (pBZr) in mononuclear cells (MNC) from blood of patients with multiple sclerosis (MS) during periods of stable and active disease and from normal controls. Most active MS patients were retested in a longitudinal study, both during a treatment with high dose steroids and while medication free. Active MS produces a significant decrease of receptor density compared with the controls whereas remission of the disease shows no effect. Four weeks of steroid treatment restore binding density to normal levels, and two weeks of drug withdrawal result in a small, but significant increase in number of the binding sites compared with the control value. We suggest that the number of pBZr in blood MNC might change during the clinical course and steroid therapy of MS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336009     DOI: 10.1007/bf02334972

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  41 in total

1.  Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis.

Authors:  K Adachi; T Kumamoto; S Araki
Journal:  Ann Neurol       Date:  1990-11       Impact factor: 10.422

2.  A study of 3H-PK 11,195 binding to "peripheral-type" benzodiazepine receptors on human lymphocytes. Evidence of decreased binding in hepatic encephalopathy.

Authors:  P Ferrero; P Rocca; A Gualerzi; P Benna; F Enrichens; G Olivero; P Mao; L Ravizza; B Bergamasco
Journal:  J Neurol Sci       Date:  1991-04       Impact factor: 3.181

Review 3.  Effects of stress on the immune system.

Authors:  D N Khansari; A J Murgo; R E Faith
Journal:  Immunol Today       Date:  1990-05

4.  Peripheral-type benzodiazepine receptors in anxiety disorders.

Authors:  P Rocca; P Ferrero; A Gualerzi; E Zanalda; G Maina; B Bergamasco; L Ravizza
Journal:  Acta Psychiatr Scand       Date:  1991-12       Impact factor: 6.392

5.  Assessment of autonomic disturbances in multiple sclerosis by measurement of heart rate responses to deep breathing and to standing.

Authors:  R Mutani; S Clemente; A Lamberti; F Monaco
Journal:  Ital J Neurol Sci       Date:  1982-07

6.  Dexamethasone suppression test abnormalities in multiple sclerosis: relation to ACTH therapy.

Authors:  A T Reder; M T Lowy; H Y Meltzer; J P Antel
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

Review 7.  MS: a CNS and systemic autoimmune disease.

Authors:  D A Hafler; H L Weiner
Journal:  Immunol Today       Date:  1989-03

Review 8.  Peripheral-type benzodiazepine receptors: a second site of action for benzodiazepines.

Authors:  K E Krueger
Journal:  Neuropsychopharmacology       Date:  1991-06       Impact factor: 7.853

9.  High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations.

Authors:  L Durelli; D Cocito; A Riccio; C Barile; B Bergamasco; G F Baggio; F Perla; M Delsedime; G Gusmaroli; L Bergamini
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

10.  Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis.

Authors:  B Anlar; J W Karaszewski; A T Reder; B G Arnason
Journal:  J Neuroimmunol       Date:  1992-02       Impact factor: 3.478

View more
  1 in total

1.  Translocator protein 18 kDa (TSPO) expression in multiple sclerosis patients.

Authors:  Erin Harberts; Dibyadeep Datta; Selby Chen; Jillian E Wohler; Unsong Oh; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2012-09-06       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.